Composition comprising at least one 15-pgdh inhibitor

Abstract

The invention relates to a cosmetic composition containing at least one 15-hydroxy-prostaglandin dehydrogenase inhibitor and cosmetically acceptable excipients. It also relates to a method of cosmetic treatment for promoting the growth and/or preventing or delaying the loss of hair, and the use of a 15-hydroxyprostaglandin dehydrogenase inhibitor for the preparation of a composition intended for controlling hair loss and/or for promoting hair regrowth.

1 . A cosmetic or pharmaceutical composition comprising at least one 15-PGDH inhibitor which is a tetrazole compound of formula (I) or (II): 
       
         
           
           
               
               
           
         
         an inorganic or organic salt thereof, wherein each of R 1  and R 2  is hydrogen or halogen; R 3  is NR 6 R′ 6 , or R 3  is naphthyl or phenyl optionally substituted with OR 9 , R 4  is naphthyl or phenyl, optionally substituted with OCH 3  or CF 3 ; R 6  is hydrogen; R′ 6  is phenyl optionally substituted with OR 9 ; 
         and R 9  is saturated, linear or branched C 1 -C 10  alkyl; 
         and physiologically acceptable excipients therefor. 
       
     
     
         2 . A cosmetic or pharmaceutical composition according to  claim 1 , wherein the compound of formula (I) or (II) is: 
       1-phenyl-2-(2-phenyl-2H-tetrazol-5-yl)ethanone having the formula: 
       
         
           
           
               
               
           
         
       
       1-(2-methoxyphenyl)-2-(2-phenyl-2H-tetrazol-5-yl)ethanone having the formula: 
       
         
           
           
               
               
           
         
       
       N-(4-methylphenyl)-2-{5-[3 (trifluoromethyl)phenyl]-2H-tetrazol-2-yl}acetamide having the formula: 
       
         
           
           
               
               
           
         
       
       N-(2-phenyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide having the formula: 
       
         
           
           
               
               
           
         
         (2-methoxyphenyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide having the formula: 
       
       
         
           
           
               
               
           
         
       
     
     
         3 . A cosmetic or pharmaceutical composition comprising at least one 15-PGDH inhibitor selected from the group consisting of: 
       Molecule A: 
       5-Amino-4,6-dichloro-2-phenylpyrimidine having the formula 
       
         
           
           
               
               
           
         
       
       Molecule B: 
       N-[7-(2-Chlorophenyl)-5-oxo-5,6,7,8-tetrahydroquinazolin-2-yl]benzamide having the formula: 
       
         
           
           
               
               
           
         
       
       1-Phenyl-2-(2-phenyl-2H-tetrazol-5-yl)ethanone having the formula: 
       
         
           
           
               
               
           
         
       
       N-(4-Methylphenyl)-2-{5-[3-(trifluoromethyl)phenyl]-2H-tetrazol-2-yl}acetamide having the formula: 
       
         
           
           
               
               
           
         
       
       N-(2-Methoxyphenyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide having the formula: 
       
         
           
           
               
               
           
         
         and physiologically acceptable excipients therefor. 
       
     
     
         4 . A composition according to  claim 1 , wherein said at least one 15-hydroxyprostaglandin dehydrogenase inhibitor is encapsulated in a structure selected from the group consisting of microspheres, nanospheres, oleosomes and nanocapsules. 
     
     
         5 . A composition according to  claim 2 , wherein said at least one 15-hydroxyprostaglandin dehydrogenase inhibitor is encapsulated in a structure selected from the group consisting of microspheres, nanospheres, oleosomes and nanocapsules. 
     
     
         6 . A composition according to  claim 3 , wherein said at least one 15-hydroxyprostaglandin dehydrogenase inhibitor is encapsulated in a structure selected from the group consisting of microspheres, nanospheres, oleosomes and nanocapsules. 
     
     
         7 . A cosmetic or pharmaceutical composition according to  claim 1 , wherein the 15-PGDH inhibitor is an inhibitor specific for 15-PGDH and wherein the ratio between the 15-PGDH inhibiting activity and the prostaglandin F synthase (PGF synthase) inhibiting activity is greater than 1. 
     
     
         8 . A cosmetic composition according to  claim 1 , in the form of a hair cream, a hair lotion, a shampoo, an after-shampoo, a hair mascara or an eyelash mascara. 
     
     
         9 . A cosmetic composition according to  claim 2 , in the form of a hair cream, a hair lotion, a shampoo, an after-shampoo, a hair mascara or an eyelash mascara. 
     
     
         10 . A cosmetic composition according to  claim 3 , in the form of a hair cream, a hair lotion, a shampoo, an after-shampoo, a hair mascara or an eyelash mascara.